GHGuoyu Huang

Guoyu Huang

*This is an algorithmically generated author record based on publicly available information.

Guoyu Huang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CDR-Informed Graph Neural Network for Plasma Metabolomics in Lung Cancer and Pulmonary Neuroendocrine Neoplasms

    by Eyad Himdiat, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, Maria Vaida

    Plasma metabolomics offers a promising avenue for the non-invasive classification of lung cancer. However, most classification frameworks treat lung cancer as a single entity, conflating non-small-cell lung cancer (NSCLC) with pulmonary neuroendocrine neoplasms (NENs), despite their distinct biology and treatment pathways. We apply a heterogeneous graph neural network to a three-class problem discriminating Control, NSCLC, and NEN from targeted plasma metabolomic profiling in 800 participants (466 NSCLC, 120 NEN, 214 Controls). Matched metabolites were annotated by Cell Danger Response (CDR) relevance class and expected direction of change, with these annotations encoded as metabolite features and direction-aware patient–metabolite edge weights. Across ten random seeds, the three-class model achieved a macro-F1 of 0.898±0.026 and macro-AUROC of 0.962±0.016. Collapsing the three-class posteriors to a cancer-versus-control score yielded an AUROC of 0.951±0.017, a sensitivity of 0.960±0.011, and an F1 score of 0.949±0.010. A separate cancer-only classifier distinguished NEN from NSCLC with an accuracy of 0.960±0.026 and an AUROC of 0.985±0.020. The gradient-times-input attribution identified one-carbon, glycine–serine, proline, and ornithine–arginine metabolic programs, with proline, C5DC, uric acid, and fumaric acid among the leading annotated metabolites. Removal of all 11 cohort-derived Class N annotations left NSCLC-versus-NEN AUROC essentially unchanged, and broader comparator analyses showed no measurable predictive advantage of the CDR prior over the otherwise matched concentration-weighted GNN. These findings indicate that predictive discrimination is driven primarily by the measured metabolomic features, whereas the CDR component provides a biologically structured framework for directional metabolite and pathway interpretation. Independent external and prospective validation is required to establish generalizability and clinical utility.

  • Open Access

    SEFA: Semantic Embedding-Based Feature Augmentation of Biomedical Language-Model Embeddings Improves Interpretable Metabolomic Prediction of Lung Cancer

    by Jiawen Wu, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, Maria Vaida

    Background/Objectives: Feature engineering remains a major challenge in metabolomics-based prediction, particularly when rich biochemical knowledge is available but underutilized. Conventional metabolomics models rely primarily on measured variables and statistically driven feature selection, overlooking the molecular and pathway context encoded in curated metabolite knowledge bases. We propose SEFA (Semantic Embedding-based Feature Augmentation), a model-agnostic framework that integrates metabolite-level textual knowledge from the Human Metabolome Database (HMDB) into structured metabolomics modeling for lung-cancer prediction. Methods: SEFA encodes HMDB metabolite descriptions as 768-dimensional MedBERT vectors and projects measured metabolite concentrations into this semantic space via concentration-weighted aggregation, producing a 928-dimensional candidate feature matrix that concatenates 11 clinical variables, 149 metabolite concentrations, and 768 semantic projection features. Sparse L1-guided feature selection reduced this representation to 24 features (2.6% of candidates) within a leakage-free cross-validation pipeline. Six classifiers were evaluated on a lung-cancer plasma metabolomics cohort of 800 participants (586 cases, 214 controls) with a stratified 80:20 split, and a controlled ablation study compared the augmented representation with a 24-metabolite-only baseline. Pathway-enrichment analysis of the metabolite sets associated with the retained embedding dimensions was performed using MetaboAnalyst 5.0. Results: Logistic regression on the 24-feature SEFA representation achieved a test ROC-AUC of 0.969, a precision-recall AUC of 0.987, and an accuracy of 94.4%, competitive with less interpretable approaches. Under the same 24-feature budget, embedding augmentation improved test ROC-AUC by 0.008, precision-recall AUC by 0.004, and accuracy by 3.1 percentage points over the metabolite-only baseline. Five retained embedding dimensions mapped onto coherent metabolic themes—sphingolipids and acylcarnitines, carnitine and glutamine metabolism, one-carbon and nitrogen handling, purine catabolism, and oxidative stress markers—and their associated metabolite sets were enriched for arginine and proline metabolism and glycine, serine, and threonine metabolism, pathways with established roles in lung-cancer biology. Conclusions: SEFA demonstrates that semantic embeddings derived from biomedical language models can convert curated metabolite annotations into patient-level features that supply complementary predictive signal while preserving biological interpretability through pathway-level analysis. The present evidence is limited to a single region-specific cohort; external, cross-platform, and cross-disease evaluation is required before broader generalization or clinical application.


  • Open Access

    Smoking-Stratified Signal Decomposition and Feature Selection for Never-Smoker Cancer Classification in a Combined Lung–Breast Metabolomics Cohort

    by Bharadwaj Popuri, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, Maria Vaida

    Metabolomic cancer classifiers trained on mixed-smoking cohorts may embed tobacco exposure signal within their predictions, degrading performance in never-smokers, a population in which lung adenocarcinoma is frequently diagnosed. We developed a two-stage framework that (i) decomposes a shared 129-metabolite panel from a combined lung–breast cancer cohort (n=1038) into cancer-specific (Signal C), smoking-specific (Signal S), and shared (Signal S∩C) components using two-way analysis of variance with Benjamini–Hochberg correction, and (ii) applies multiple feature-selection strategies to identify the minimal Signal C subset that surpasses the all-metabolite baseline for never-smoker cancer detection. Two-way ANOVA partitioned 54 of 129 metabolites as cancer-specific (Signal C) and 57 as smoking-specific (Signal S), suggesting that nearly half of the shared panel is influenced by tobacco exposure. A model of 19 Signal C metabolites, selected by composite rank aggregation across four feature-selection methods and trained with gradient-boosted trees, achieved a never-smoker area under the receiver operating characteristic curve (AUC) of 0.907 on pooled out-of-fold predictions (0.910 as a mean across folds) against an all-metabolite baseline of 0.895, using 85% fewer metabolite measurements. The signal decomposition is a reproducible and interpretable way to identify metabolites whose case–control differences are not attributable to tobacco exposure, and it permits a substantial reduction in panel size.


  • Open Access

    SEFA: Semantic Embedding-Based Feature Augmentation of Biomedical Language-Model Embeddings Improves Interpretable Metabolomic Prediction of Lung Cancer

    by Jiawen Wu, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, Maria Vaida

    Feature engineering remains a major challenge in metabolomics-based prediction, particularly when rich biochemical knowledge is available but underutilized. Conventional metabolomics models rely primarily on measured variables and statistically driven feature selection, often overlooking the molecular and pathway context encoded in curated metabolite knowledge bases. Here, we propose SEFA (Semantic Embedding–based Feature Augmentation), a model agnostic feature engineering framework that integrates metabolite level textual knowledge into structured metabolomics and clinical modeling for lung cancer. SEFA leverages semantic embeddings derived from external metabolite resources to enrich feature construction through embedding based semantic projection and knowledge-guided feature selection, yielding a compact and biologically interpretable feature representation. Using a targeted lung cancer metabolomics dataset, we evaluate SEFA across multiple learning algorithms, including linear, kernel based, tree based, and neural network models, and show that embedding informed feature construction consistently improves prediction performance over approaches that rely solely on tabular metabolite and clinical features. Analysis of the selected features revealed enrichment in pathways including arginine and proline metabolism and glycine, serine, and threonine metabolism, indicating that the embedding derived feature representations capture biologically relevant metabolic processes associated with lung cancer. These results support the use of semantic knowledge in metabolomics feature engineering and position SEFA as a practical, general machine learning framework for enhancing predictive modeling while preserving biological interpretability through pathway level analysis.


  • Open Access

    M-GNN: A Graph Neural Network Framework for Lung Cancer Detection Using Metabolomics and Heterogeneous Graph Modeling

    by Maria Vaida, Jiawen Wu, Eyad Himdiat, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, W. Rand Ford

    Lung cancer remains the leading cause of cancer-related mortality worldwide, with early detection critical for improving survival rates, yet conventional methods like CT scans often yield high false-positive rates. This study introduces M-GNN, a graph neural network framework leveraging GraphSAGE, to enhance early lung cancer detection through metabolomics. We constructed a heterogeneous graph integrating metabolomics data from 800 plasma samples (586 cases, 214 controls) with demographic features and Human Metabolome Database annotations, employing GraphSAGE and GAT layers for inductive learning on 107 metabolites, pathways, and diseases. M-GNN achieved a test accuracy of 89% and an ROC-AUC of 0.92, with rapid convergence within 400 epochs and robust performance across ten random seeds; key predictors included age, height, choline, Valine, Betaine, and Fumaric Acid, reflecting smoking and metabolic dysregulation. This framework offers a scalable, interpretable tool for precision oncology, surpassing benchmarks by capturing complex biological interactions, though limitations like synthetic data biases and computational demands suggest future validation with real-world cohorts and optimization. M-GNN advances lung cancer screening, promising improved survival through early detection and personalized strategies.


  • Open Access

    Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection

    by Lun Zhang, Jiamin Zheng, Rashid A. Bux, Jean-François Haince, Claudia Torres-Calzada, Rupasri Mandal, Andrew Maksymiuk, Guoyu Huang, Paramjit S. Tappia, Philippe Joubert, et al.

    Early detection of lung cancer significantly improves survival, yet current screening methods have limitations. This study aimed to identify a robust panel of plasma metabolites for early-stage non-small cell lung cancer (NSCLC) diagnosis using a large, clinically diverse patient cohort. A total of 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls (including healthy individuals and patients with non-cancerous lung diseases) were analyzed using targeted, quantitative mass spectrometry-based metabolomics and used as the discovery cohort. An independent set of 216 plasma samples served as the validation cohort. Logistic regression (LR) models developed from the discovery set using ten metabolites achieved area under the receiver-operating characteristic curve (AUROC) values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, stage I–II, and stage I NSCLC patients from controls, respectively. Incorporating smoking history further improved model performance. The validation cohort confirmed the model’s robustness, demonstrating high sensitivity and specificity for early-stage detection. These results support the potential of metabolomic biomarkers as a minimally invasive, accurate tool for early NSCLC diagnosis. This approach may complement current screening methods, enabling earlier intervention and improved patient outcomes. Further studies are warranted to validate these findings in more diverse populations and real-world clinical settings.


  • Open Access

    M-GNN: A Graph Neural Network Framework for Lung Cancer Detection Using Metabolomics and Heterogeneous Graph Modeling

    by Maria Vaida, Jiawen Wu, Eyad Himdiat, Jean-Francoise Haince, Rashid A Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, W Rand Ford

    Lung cancer remains the leading cause of cancer-related mortality worldwide, with early detection critical for improving survival rates, yet conventional methods like CT scans often yield high false-positive rates. This study introduces M-GNN, a Graph Neural Network framework leveraging GraphSAGE, to enhance early lung cancer detection through metabolomics. We constructed a heterogeneous graph integrating metabolomics data from 800 plasma samples (586 cases, 214 controls) with demographic features and Human Metabolome Database annotations, employing GraphSAGE and GAT layers for inductive learning on 107 metabolites, pathways, and diseases. M-GNN achieved a test accuracy of 93% and an ROC-AUC of 0.96, with rapid convergence within 400 epochs and robust performance across ten random seeds; key predictors included cigarette pack years, choline, and taurine, reflecting smoking and metabolic dysregulation. This framework offers a scalable, interpretable tool for precision oncology, surpassing benchmarks by capturing complex biological interactions, though limitations like synthetic data biases and computational demands suggest future validation with real-world cohorts and optimization. M-GNN advances lung cancer screening, promising improved survival through early detection and personalized strategies.


  • Open Access

    Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status

    by Kamala K. Arumalla, Jean-François Haince, Rashid A. Bux, Guoyu Huang, Paramjit S. Tappia, Bram Ramjiawan, W. Randolph Ford, Maria Vaida

    Breast cancer is a global concern as a leading cause of death for women. Early and precise diagnosis can be vital in handling the disease efficiently. Breast cancer subtyping based on estrogen receptor (ER) status is crucial for determining prognosis and treatment. This study uses metabolomics data from plasma samples to detect metabolite biomarkers that could distinguish ER-positive from ER-negative breast cancers in a non-invasive manner. The dataset includes demographic information, ER status, and metabolite levels from 188 breast cancer patients and 73 healthy controls. Recursive Feature Elimination (RFE) with a Random Forest (RF) classifier identified an optimal subset of 30 features—29 biomarkers and age—that achieved the highest area under the curve (AUC). To address the class imbalance, Gaussian noise-based augmentation and Adaptive Synthetic Oversampling (ADASYN) were applied, ensuring balanced representation during training. Four machine learning (ML) algorithms—Random Forest, Support Vector Classifier (SVC), XGBoost, and Logistic Regression (LR)—were evaluated using grid search. The Random Forest classifier emerged as the top performer, achieving an AUC of 0.95 and an accuracy of 93%. These results suggest that ML has great promise for identifying specific metabolites linked to ER expression, paving the development of a novel analytical tool that can minimize current challenges in identifying ER status, and improve the precision of breast cancer subtyping.


  • Open Access

    Identification of a Novel Biomarker Panel for Breast Cancer Screening

    by Maria Vaida, Kamala K. Arumalla, Pavan Kumar Tatikonda, Bharadwaj Popuri, Rashid A. Bux, Paramjit S. Tappia, Guoyu Huang, Jean-François Haince, W. Randolph Ford

    Breast cancer remains a major public health concern, and early detection is crucial for improving survival rates. Metabolomics offers the potential to develop non-invasive screening and diagnostic tools based on metabolic biomarkers. However, the inherent complexity of metabolomic datasets and the high dimensionality of biomarkers complicates the identification of diagnostically relevant features, with multiple studies demonstrating limited consensus on the specific metabolites involved. Unlike previous studies that rely on singular feature selection techniques such as Partial Least Square (PLS) or LASSO regression, this research combines supervised and unsupervised machine learning methods with random sampling strategies, offering a more robust and interpretable approach to feature selection. This study aimed to identify a parsimonious and robust set of biomarkers for breast cancer diagnosis using metabolomics data. Plasma samples from 185 breast cancer patients and 53 controls (from the Cooperative Human Tissue Network, USA) were analyzed. This study also overcomes the common issue of dataset imbalance by using propensity score matching (PSM), which ensures reliable comparisons between cancer and control groups. We employed Univariate Naïve Bayes, L2-regularized Support Vector Classifier (SVC), Principal Component Analysis (PCA), and feature engineering techniques to refine and select the most informative features. Our best-performing feature set comprised 11 biomarkers, including 9 metabolites (SM(OH) C22:2, SM C18:0, C0, C3OH, C14:2OH, C16:2OH, LysoPC a C18:1, PC aa C36:0 and Asparagine), a metabolite ratio (Kynurenine-to-Tryptophan), and 1 demographic variable (Age), achieving an area under the ROC curve (AUC) of 98%. These results demonstrate the potential for a robust, cost-effective, and non-invasive breast cancer screening and diagnostic tool, offering significant clinical value for early detection and personalized patient management.


  • Open Access

    Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status

    by Kamala Arumalla, Jean-Francois Haince, Rashid A Bux, Guoyu Huang, Paramjit S. Tappia, W. Rand Ford, Maria L. Vaida

    Breast cancer is a global concern as a leading cause of death for women. Early and precise diagnosis can be vital in handling the disease efficiently. Breast cancer subtyping based on estrogen receptor (ER) status is crucial for determining prognosis and treatment. This study uses metabolomics data from plasma samples to detect metabolite biomarkers that could distinguish ER-positive from ER-negative breast cancers in a non-invasive manner. The dataset includes demographic information, ER status, and metabolite levels from 188 breast cancer patients and 73 healthy controls. Supervised, unsupervised, and ensemble machine learning (ML) algorithms were applied to identify key metabolites associated with ER status, including Support Vector Machines (SVM), Multidimensional Scaling (MS), Logistic Regression (LR), and Ensemble learning. The most informative feature set, containing 28 biomarkers and two demographic factors, achieved an impressive 96% accuracy and an area under the curve (AUC) of 93% using the Logistic Regression model. These results suggest that ML has great promise for identifying specific metabolites linked to ER expression, paving the development of a novel analytical tool that can minimize current lab challenges such as analytical sample handling, subjective results interpretation, biological heterogeneity of the tumor in a non-invasive and efficient manner aiding in more precise diagnosis of breast cancer.